Search the GHTC website

Global health R&D delivers for Wisconsin

US government investment in global health R&D has delivered

$191.3 milion
to Wisconsin research institutions
2,500+ new jobs
for Wisconsin
Wisconsin's top USG-funded global health R&D institutions

Wisconsin's top USG-funded global health R&D institutions

University of Wisconsin-Madison
$160.1 million
Medical College of Wisconsin
$15.1 million
Godx Inc.
$4.6 million
ioGenetics LLC
$4 million
Lucigen Corporation*
$2.2 million
Salus Discovery
$1.5 million
Versiti Blood Center of Wisconsin
$1.5 million
Concordia University Wisconsin
$488 thousand
Scarab Genomics LLC
$470 thousand
Cascade Biosystems Inc.
$448 thousand
BellBrook Labs
$422 thousand
Intuitive Biosciences
$300 thousand
Terra Bioforge (formerly Varigen Biosciences Corporation)
$268 thousand
DNASTAR Inc. (formerly DNASTAR Bioinformatics Software)
$12 thousand
Marshfield Clinic Research Institute
$12 thousand

Wisconsin's top areas of global health R&D by USG funding

Diarrheal diseases
Flioviral diseases (including Ebola, Marburg)
Neglected tropical diseases
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Salmonella infections
Arenaviral hemorrhagic fevers (including Lassa fever)
Bacterial pneumonia & meningitis
Cryptococcal meningitis
Multi-disease/health area R&D
Other coronaviruses (including MERS, SARS)
Reproductive health
Global health R&D at work in Wisconsin

University of Wisconsin at Madison scientists are leading a research consortium focused on developing a pan-coronavirus vaccine that could protect against multiple known and yet-unknown coronaviruses. The consortium was one of three teams chosen by the US National Institutes of Health to simultaneously work on this goal. Coronaviruses are the viral family responsible for not only the COVID-19 pandemic but also the epidemics of Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). A pan-coronavirus vaccine is an important tool that would offer some level of protection to populations if a new coronavirus epidemic or pandemic occurs, buying scientists time to develop a pathogen-specific vaccine.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: US Department of Energy